MediciNova (MNOV) Q3 2024 earnings summary

Executive summary

• Focused on developing novel therapeutics for serious diseases, with a primary commercial focus on the U.S. market.

• Pipeline includes MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic diseases, plus MN-221 and MN-029 for asthma and cancer.

• Strategy emphasizes advancing MN-166 and MN-001 through investigator-sponsored and grant-funded trials, and seeking strategic partnerships.

• Accumulated deficit reached $423.9 million as of September 30, 2024; expects continued net losses as development progresses.

Financial highlights

• Cash and cash equivalents were $42.3 million as of September 30, 2024, down from $51.0 million at December 31, 2023.

• Revenues were $0.0 million for Q3 2024, compared to $1.0 million in Q3 2023, due to a prior milestone payment.

• Research, development, and patents expenses increased to $1.9 million in Q3 2024 from $0.8 million in Q3 2023, mainly due to ALS and safety test costs.

• General and administrative expenses were $1.5 million in Q3 2024, up from $1.4 million in Q3 2023.

• Net loss for Q3 2024 was $2.85 million, or $(0.06) per share, compared to $0.72 million, or $(0.01) per share, in Q3 2023.

• Net cash used in operating activities for the nine months ended September 30, 2024 was $8.7 million, compared to $6.9 million in the prior year period.

Outlook and guidance

• Working capital is expected to be sufficient to fund operations through at least the end of 2025.

• No assurance that current capital resources will cover all planned R&D programs.

• Expects to incur substantial net losses for several years as development continues.